| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
Lars Bullinger
|
|||||||
| GSE206802 |
Concomitant Cytotoxic Effector Differentiation of CD4+ and CD8+ T Cells in Response to EBV-Infected B Cells
|
10 | Lars Bullinger | Aug 26, 2022 | ||||
| GSE111678 |
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
|
260 | Lars Bullinger | Dec 21, 2018 | ||||
| GSE119437 |
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells
|
12 | Lars Bullinger | Dec 21, 2018 | ||||
| GSE85732 |
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells [HG-U133_Plus_2]
|
8 | Lars Bullinger | Dec 31, 2016 | ||||
| GSE85733 |
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells [GenomeWideSNP_6]
|
6 | Lars Bullinger | Dec 31, 2016 | ||||
| GSE85734 |
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
|
14 | Lars Bullinger | Dec 31, 2016 | ||||
| GSE70124 |
Genomic structure, evolution and molecular classification of acute myeloid leukemia
|
46 | Lars Bullinger | Jun 08, 2016 | ||||
| GSE68043 |
PI3 Kinase and FOXO1 activity differentially control B cells in the germinal center light and dark zone
|
12 | Lars Bullinger | Nov 23, 2015 | ||||
| GSE62533 |
Inhibitor of apoptosis proteins as promising therapeutic targets in chronic lymphocytic leukemia
|
12 |
|
Lars Bullinger | Mar 31, 2015 | |||
| GSE39363 |
A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy
|
13 | Lars Bullinger | Dec 31, 2014 | ||||
| GSE46819 |
Inhibitor of apoptosis protein antagonist BV6 – potential for new combinatorial treatment strategies in acute myeloid leukemia
|
24 | Lars Bullinger | Dec 31, 2014 | ||||
| GSE54223 |
Phospholipase Cγ1 is crucially required for EpoR/JAK2 controlled erythropoietic differentiation.
|
12 | Lars Bullinger | Dec 31, 2014 | ||||
| GSE56241 |
Distinct biological and transcriptional features of FLT3-ITD variants in vitro and in vivo
|
5 | Lars Bullinger | Dec 31, 2014 | ||||
| GSE60695 |
Transcriptional changes induced by KRAS mutants
|
12 | Lars Bullinger | Dec 31, 2014 | ||||
| GSE43258 |
PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17)
|
6 | Lars Bullinger | Mar 10, 2013 | ||||
| GSE40939 |
Leukemogenesis by CDX2 involves KLF4 repression and deregulated PPARgamma signaling.
|
10 | Lars Bullinger | Dec 21, 2012 | ||||
| GSE35219 |
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
|
13 | Lars Bullinger | Aug 14, 2012 | ||||
| GSE39730 |
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance
|
12 | Lars Bullinger | Aug 03, 2012 | ||||
| GSE11572 |
Klf4
|
12 | Lars Bullinger | Jul 31, 2012 | ||||
| GSE32246 |
TET2 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis of the AML Study Group (AMLSG)
|
333 | Lars Bullinger | Dec 31, 2011 |
